10X Genomics is a biotechnology company that specializes in genomic analysis, providing tools and technologies for researchers in the life sciences sector. The company develops innovative products that enable high-resolution analysis of biological systems, allowing scientists to explore complex interactions at the single-cell level. By offering advanced sequencing and gene expression solutions, 10X Genomics supports a wide range of applications in genomics, transcriptomics, and immunology, aiming to accelerate the discovery of new insights into health and disease. Read More
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
What a time it’s been for 10x Genomics. In the past six months alone, the company’s stock price has increased by a massive 73.9%, reaching $15.53 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
10x Genomics delivered results in Q3 that exceeded Wall Street’s expectations, driven by robust demand in spatial biology and a steady performance in single-cell consumables. Management attributed the outperformance to strong adoption of the Xenium platform, which saw double-digit consumable growth, as well as the successful launch of new single-cell assays like Flex and On-Chip Multiplexing. CEO Serge Saxonov highlighted that despite continued macroeconomic challenges and cautious customer spending, both the number of runs and average spend per run increased, particularly in spatial, while ongoing cost controls improved operating margins.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
jumped 0.6% in the afternoon session after Canaccord Genuity Group raised its price target on the stock. The analyst firm lifted its target to $19.00 from $16.00 and kept a "buy" rating on the shares.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at PacBio (NASDAQ:PACB) and the best and worst performers in the life sciences tools & services industry.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
jumped 14.3% in the afternoon session after the company reported third-quarter financial results that beat Wall Street's expectations and provided an upbeat revenue forecast for the fourth quarter.
Biotech company 10x Genomics (NASDAQ:TXG) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the midpoint) was surprisingly good and 3.5% above what analysts were expecting. Its GAAP loss of $0.22 per share was 22.7% above analysts’ consensus estimates.
Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the midpoint) was surprisingly good and 3.5% above what analysts were expecting. Its GAAP loss of $0.22 per share was 22.3% above analysts’ consensus estimates.
The Chan Zuckerberg Initiative (CZI), founded by Priscilla Chan and Mark Zuckerberg, is placing artificial intelligence at the very heart of its audacious mission: to cure, prevent, or manage all diseases by the end of the century. This monumental philanthropic endeavor is not merely dabbling in AI; it's architecting a future where advanced computational models [...]
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 13.5% return has trailed the S&P 500 by 9.4 percentage points.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
jumped 6% in the morning session after BofA Securities maintained its "Buy" rating on the stock, even while lowering its price target.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
jumped 1.5% in the afternoon session after it announced a strategic partnership with SPT Labtech, a laboratory automation company, to provide automated workflows for single-cell research.
